Amedisys (NASDAQ:AMED) Upgraded to “Buy” by StockNews.com

StockNews.com upgraded shares of Amedisys (NASDAQ:AMED) from a hold rating to a buy rating in a research note released on Saturday morning.

Several other brokerages have also commented on AMED. Raymond James reaffirmed a market perform rating on shares of Amedisys in a research report on Tuesday, March 26th. Royal Bank of Canada lifted their target price on Amedisys from $97.00 to $100.00 and gave the stock an outperform rating in a research report on Monday, March 25th. Finally, Cantor Fitzgerald reissued a neutral rating and issued a $101.00 price target on shares of Amedisys in a report on Thursday, April 25th. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of Hold and a consensus price target of $100.80.

Amedisys Trading Up 0.0 %

Shares of AMED stock opened at $92.36 on Friday. The stock has a market cap of $3.02 billion, a P/E ratio of -144.31, a P/E/G ratio of 3.43 and a beta of 0.84. Amedisys has a fifty-two week low of $73.10 and a fifty-two week high of $96.44. The business has a fifty day simple moving average of $92.30 and a 200-day simple moving average of $93.32. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.31.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The company had revenue of $571.41 million during the quarter, compared to analysts’ expectations of $565.38 million. During the same period in the previous year, the firm posted $1.00 earnings per share. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, analysts forecast that Amedisys will post 4.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Banque Cantonale Vaudoise purchased a new position in Amedisys during the 1st quarter worth approximately $60,000. Cetera Trust Company N.A bought a new stake in Amedisys during the fourth quarter valued at about $215,000. CWM LLC lifted its position in shares of Amedisys by 40.4% during the 4th quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock worth $250,000 after purchasing an additional 757 shares during the last quarter. Contravisory Investment Management Inc. bought a new stake in Amedisys during the 4th quarter valued at approximately $258,000. Finally, Mesirow Institutional Investment Management Inc. grew its stake in shares of Amedisys by 9.9% in the fourth quarter. Mesirow Institutional Investment Management Inc. now owns 2,844 shares of the health services provider’s stock worth $270,000 after acquiring an additional 257 shares during the last quarter. Institutional investors own 94.36% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.